NEW YORK, Jan 12, 2026, 05:28 EST — Premarket
- Hims & Hers shares slipped roughly 2.2% in premarket action following a 6.4% drop on Friday. (StockAnalysis)
- Investors are considering if Amazon’s decision to offer Novo Nordisk’s Wegovy pill ramps up competition in the online weight-loss market. (Reuters)
- All eyes now on Hims’ upcoming earnings report for clues on any shifts in GLP-1 growth trajectory and budget strategies. (MarketBeat)
Shares of Hims & Hers Health, Inc. slipped 2.2% in premarket trading Monday, hitting $31.00. The stock had already fallen 6.4% on Friday to $31.69 amid heavy volume. (StockAnalysis)
The selloff late in the week came after Amazon Pharmacy began offering Novo Nordisk’s newly approved Wegovy weight-loss pill via insurance plans and a cash-pay option, opening yet another major channel in a market Hims has heavily relied on for growth. (Reuters)
This is crucial now since investors see weight loss as Hims’ key growth driver: it attracts fresh users but can also squeeze margins when rivals push platforms to ramp up marketing and fulfillment costs.
GLP-1 drugs — which mimic a gut hormone to curb appetite — have propelled telehealth further into everyday use. The shift to pills also alters the game: no more needles, and pricing comparisons become simpler.
Amazon Pharmacy announced that customers with commercial insurance could pay as little as $25 for a month’s supply, while cash payments start at $149 monthly. The service offers delivery in all 50 states, with nearly half of U.S. customers eligible for same-day delivery. “By offering Wegovy through both insurance and a straightforward cash-pay option, we’re giving people more choice, greater transparency, and fewer barriers to care,” said Tanvi Patel, vice president and general manager of Amazon Pharmacy. (Business Wire)
Hims is aiming high. Back in November, the company projected $725 million in revenue by 2026 from its GLP-1 weight-loss drug. CEO Andrew Dudum said the growth opportunities are coming faster than expected, and the company is fully committed. Morningstar’s Keonhee Kim noted that Hims is “willing to allocate a lot of capital at the cost of margins” to push growth. (Reuters)
The business has also come under scrutiny for compounded drugs — pharmacy-made alternatives sold during shortages of branded medicines. Novo Nordisk pulled the plug on its short-lived partnership to sell Wegovy through Hims in June 2025. Truist analyst Jailendra Singh flagged at the time that the split might “anticipate a decline in traffic” and hit Hims’ compounding operations. (Reuters)
Traders will be watching if Monday’s early dip extends into the open, and whether Hims can retain its new weight-loss customers without pushing selling costs higher again.
The downside is straightforward: if pill access ramps up fast and cash-pay customers chase the lowest price, Hims might see rising churn and increased marketing costs—precisely when investors want to see margin stability.
The next major catalyst is earnings. Hims hasn’t officially announced its next report date, but MarketBeat expects it on Feb. 23 after markets close. Investors will be watching closely for updates on GLP-1 demand, pricing, and 2026 spending plans. (MarketBeat)
